LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway

Long non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in colorectal cancer progression

(2018) Yang Li et al.   Journal of Hematology & Oncology

Down-regulated miR-26a promotes proliferation, migration, and invasion via negative regulation of MTDH in esophageal squamous cell carcinoma

(2017) Chenchen Yang et al.   FASEB JOURNAL

Targeting PI3K/AKT pathway in triple-negative breast cancer

(2017) Suzette Delaloge et al.   LANCET ONCOLOGY

Long noncoding RNA LINC01296 is associated with poor prognosis in prostate cancer and promotes cancer-cell proliferation and metastasis

(2017) Jie Wu et al.   OncoTargets and Therapy

Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer

(2017) Yang Li et al.   Cell Death & Disease

Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer

(2017) Anna Katharina Seitz et al.   Scientific Reports

Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA

(2016) Le Qu et al.   CANCER CELL

A functional polymorphism inlnc-LAMC2-1:1confers risk of colorectal cancer by affecting miRNA binding

(2016) Jing Gong et al.   CARCINOGENESIS

PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells

(2016) Jana Samarin et al.   HEPATOLOGY

LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner

(2016) Wen-Tao Wang et al.   Journal of Hematology & Oncology

MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2

(2016) De-Ning Ma et al.   Journal of Hematology & Oncology

The long non-coding RNA, SNHG6-003, functions as a competing endogenous RNA to promote the progression of hepatocellular carcinoma

(2016) C Cao et al.   ONCOGENE

The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis

(2015) Lisa M. Ooms et al.   CANCER CELL

The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL

(2015) K Balakrishnan et al.   LEUKEMIA

Long non-coding RNA LINC01296 is a potential prognostic biomarker in patients with colorectal cancer

(2015) Jia-jun Qiu et al.   TUMOR BIOLOGY

The Noncoding RNA Revolution—Trashing Old Rules to Forge New Ones

(2014) Thomas R. Cech et al.   CELL

GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity

(2014) Mei-Chun Lin et al.   ORAL ONCOLOGY

MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway

(2013) Xin Yang et al.   HEPATOLOGY

Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy

(2012) Satyanarayana Rachagani et al.   Journal of Hematology & Oncology

Mucin Glycosylating Enzyme GALNT2 Regulates the Malignant Character of Hepatocellular Carcinoma by Modifying the EGF Receptor

(2011) Y.-M. Wu et al.   CANCER RESEARCH

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

(2011) Hiromichi Ebi et al.   JOURNAL OF CLINICAL INVESTIGATION

Implementing prognostic and predictive biomarkers in CRC clinical trials

(2011) Sandra Van Schaeybroeck et al.   Nature Reviews Clinical Oncology

Critical Roles of Mucin 1 Glycosylation by Transactivated PolypeptideN-Acetylgalactosaminyltransferase 6 in Mammary Carcinogenesis

(2010) Jae-Hyun Park et al.   CANCER RESEARCH

Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis

(2010) Rajnish A. Gupta et al.   NATURE

Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours

(2008) Ashish V. Kalra et al.   EUROPEAN JOURNAL OF CANCER